Karyopharm Therapeutics is a clinical-stage biopharmaceutical company developing Selective Inhibitors of Nuclear Export (SINE) for treatment of advanced hematologic and solid tumors. Founded in late 2008 and based in Natick, Massachusetts, the company is led by CEO Michael Kauffman, M.D., Ph.D. Karyopharm is currently testing KPT-330 in two separate Phase 1 trials and is testing the related SINE KPT-335 in a pivotal oral study for dogs with Non-Hodgkin’s Lymphoma. The company is also evaluating SINEs in autoimmune, viral and dermatologic disorders. It raised $48.2M in a Series B to advance its pipeline of novel SINE drug candidates. Proceeds are intended to fund continued clinical development across its oncology and other therapeutic programs. Karyopharm develops small-molecule modulators of nuclear transport, including oral selective inhibitors of nuclear export (SINE) targeting various cancers. The company is also evaluating related transport modulators for dermatologic, inflammatory, and viral disorders. It completed a $10M Series A2 financing that complements a $20M Series A announced a year earlier. The proceeds are intended to expand a planned Phase I program targeted to begin in mid‑2012. Karyopharm was founded in 2008 and is based in Natick, Massachusetts. Karyopharm Therapeutics is an oncology company focused on developing modulators of nuclear transport as therapies for cancer, inflammatory and other diseases. The company discovered and optimized a series of selective inhibitors of nuclear export (SINE) that target the CRM1 protein using its computational chemistry platform. The recent determination of the 3-dimensional structure of the nuclear pore complex has made mechanisms of nuclear transport more apparent and informed their work. Karyopharm plans to expand its research and development platform and to drive its first drug candidates into the clinic. The company was founded in 2009 and is based in Newton, Massachusetts. Financially, it completed a $20M Series A financing following approximately $1M in angel investments.

Total raised

$78M

Funding rounds

3

Latest round

Series B

Latest activity

May 2013